【Abstract】 Background and objective Small cell lung cancer (SCLC) is the most malignant neuroendocrine tumor but highly sensitive to chemotherapy and radiotherapy. At present, the standard first-line chemotherapy regimen of extensivestage SCLC is platinum combined etoposide regimen. However, most patients who receive first-line chemotherapy will relapse within one to two years. Once recurrent, it indicates poor prognosis. In this study, we analyzed the survival among all extensivestage SCLC and patients who received first-line chemotherapy and determined prognostic factors. Methods Total of 394 patients who were diagnosed as extensive-stage small cell lung cancer from February 200 to December 20 hospitalized in Peking Union Medical College Hospital were collected. Kaplan-Meier method was used to calculate the overall survival (OS) and progression-free survival (PFS). Univariate analysis and Cox regression analysis were used to detect the influence factors of survival. Results The median OS of all extensive-stage small cell lung cancer was 4.8 months; -year, 2-year and 5-year survival rates were 58.9%, 27.2% and 7.8%, respectively. According to the results of univariate and Cox multivariate analysis, OS of extensive-stage SCLC was closely associated with age (P=0.006), ECOG PS (P=0.02), liver metastasis (P<0.00), bone metastasis (P<0.00) and chemotherapy (P<0.00). The mortality risk of patients who didn't receive chemotherapy was 4.99 times higher than that who received; the mortality risk of patients without liver, bone metastasis was reduced by approximately 作者单位：00730 北京，中国医学科学院北京协和医院呼吸内科（马满姣，王孟昭，徐燕，刘慧慧，李龙芸，钟巍，张力，赵静，王华竹）；
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Chin J Lung Cancer, Januar y 204, Vol.7, No. 中 国 肺 癌 杂 志 2 0 4 年 月 第 7 卷 第 期 50 percent. The first-line chemotherapy was mainly EP (DDP+VP-6) or CE (CBP+VP-6) regimens (accounting for 82.8%) with 4-6 cycles. The median OS and PFS in first-line chemotherapy were 5. months and 7.5 months, respectively. The result of Cox regression analysis indicated that OS in first-line chemotherapy was remarkably related to smoking history (P=0.04), liver metastasis (P<0.00), bone metastasis (P<0.00), chemotherapy cycle number (P<0.00); PFS was relevant with smoking history (P=0.003), liver metastasis (P=0.00), bone metastasis (P<0.00), chemotherapy cycle number (P<0.00).
Thoracic radiotherapy was not an independent influence factor of OS and PFS in extensive-stage small cell lung cancer. Conclusion The patients who were younger than 60-year old, with good KPS, absence of liver and bone metastasis had better prognosis. Patients should receive chemotherapy with first-line standard regimen (CE/EP regimen). It was beneficial to survival if the effect of first-line chemotherapy was SD or PR-CR and the proper chemotherapy cycle number was 4-6 cycles. The role of thoracic radiotherapy in extensive-stage small cell lung cancer needed to be investigated further. Compare with patients who were more than 60 years old, whose ECOG performance status 2-4, who were present with liver metastasis and bone metastasis and who received chemotherapy, respectively.
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